Zhi-Zheng Wang, Jun Weng, Jing Qi, Xin-Xin Fu, Ban-Bin Xing, Yang Hu, Chun-Hsiang Huang, Chin-Yu Chen, Zigong Wei
{"title":"通过计算设计,在结构指导下发现具有抗诺卡氏菌活性的新型 dUTP 酶抑制剂。","authors":"Zhi-Zheng Wang, Jun Weng, Jing Qi, Xin-Xin Fu, Ban-Bin Xing, Yang Hu, Chun-Hsiang Huang, Chin-Yu Chen, Zigong Wei","doi":"10.1080/14756366.2024.2411573","DOIUrl":null,"url":null,"abstract":"<p><p>The zoonosis caused by <i>Nocardia</i> is increasing seriously. But commonly used antibiotic drugs often lead to resistance. <i>N. seriolae</i> dUTPase (<i>Ns</i>dUTPase) plays a key role in the proliferation of <i>Nocardia</i>, and was regarded as a potent drug target. However, there was little report about the <i>Ns</i>dUTPase inhibitors. In this study, we discovered a series of novel <i>Ns</i>dUTPase inhibitors to fight against <i>Nocardia</i>. The first crystal structure of <i>Ns</i>dUTPase was released, and a structure-based computational design was performed. Compounds <b>4b</b> and <b>12b</b> exhibited promising activities towards <i>Ns</i>dUTPase (IC<sub>50</sub> = 0.99 μM and 0.7 μM). In addition, they showed satisfied anti-<i>Nocardia</i> activity (MIC value ranges from 0.5 to 2 mg/L) and low cytotoxicity, which were better than approved drugs oxytetracycline and florfenicol. Molecular modelling study indicated that hydrophobic interaction might be the main contribution for ligand binding. Our results suggested that <i>Ns</i>dUTPase inhibitors might be a useful way to repress <i>Nocardia</i>.</p>","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":"39 1","pages":"2411573"},"PeriodicalIF":5.6000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11486130/pdf/","citationCount":"0","resultStr":"{\"title\":\"Structure-guided discovery of novel dUTPase inhibitors with anti-<i>Nocardia</i> activity by computational design.\",\"authors\":\"Zhi-Zheng Wang, Jun Weng, Jing Qi, Xin-Xin Fu, Ban-Bin Xing, Yang Hu, Chun-Hsiang Huang, Chin-Yu Chen, Zigong Wei\",\"doi\":\"10.1080/14756366.2024.2411573\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The zoonosis caused by <i>Nocardia</i> is increasing seriously. But commonly used antibiotic drugs often lead to resistance. <i>N. seriolae</i> dUTPase (<i>Ns</i>dUTPase) plays a key role in the proliferation of <i>Nocardia</i>, and was regarded as a potent drug target. However, there was little report about the <i>Ns</i>dUTPase inhibitors. In this study, we discovered a series of novel <i>Ns</i>dUTPase inhibitors to fight against <i>Nocardia</i>. The first crystal structure of <i>Ns</i>dUTPase was released, and a structure-based computational design was performed. Compounds <b>4b</b> and <b>12b</b> exhibited promising activities towards <i>Ns</i>dUTPase (IC<sub>50</sub> = 0.99 μM and 0.7 μM). In addition, they showed satisfied anti-<i>Nocardia</i> activity (MIC value ranges from 0.5 to 2 mg/L) and low cytotoxicity, which were better than approved drugs oxytetracycline and florfenicol. Molecular modelling study indicated that hydrophobic interaction might be the main contribution for ligand binding. Our results suggested that <i>Ns</i>dUTPase inhibitors might be a useful way to repress <i>Nocardia</i>.</p>\",\"PeriodicalId\":15769,\"journal\":{\"name\":\"Journal of Enzyme Inhibition and Medicinal Chemistry\",\"volume\":\"39 1\",\"pages\":\"2411573\"},\"PeriodicalIF\":5.6000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11486130/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Enzyme Inhibition and Medicinal Chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14756366.2024.2411573\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/10/10 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Enzyme Inhibition and Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14756366.2024.2411573","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/10 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
Structure-guided discovery of novel dUTPase inhibitors with anti-Nocardia activity by computational design.
The zoonosis caused by Nocardia is increasing seriously. But commonly used antibiotic drugs often lead to resistance. N. seriolae dUTPase (NsdUTPase) plays a key role in the proliferation of Nocardia, and was regarded as a potent drug target. However, there was little report about the NsdUTPase inhibitors. In this study, we discovered a series of novel NsdUTPase inhibitors to fight against Nocardia. The first crystal structure of NsdUTPase was released, and a structure-based computational design was performed. Compounds 4b and 12b exhibited promising activities towards NsdUTPase (IC50 = 0.99 μM and 0.7 μM). In addition, they showed satisfied anti-Nocardia activity (MIC value ranges from 0.5 to 2 mg/L) and low cytotoxicity, which were better than approved drugs oxytetracycline and florfenicol. Molecular modelling study indicated that hydrophobic interaction might be the main contribution for ligand binding. Our results suggested that NsdUTPase inhibitors might be a useful way to repress Nocardia.
期刊介绍:
Journal of Enzyme Inhibition and Medicinal Chemistry publishes open access research on enzyme inhibitors, inhibitory processes, and agonist/antagonist receptor interactions in the development of medicinal and anti-cancer agents.
Journal of Enzyme Inhibition and Medicinal Chemistry aims to provide an international and interdisciplinary platform for the latest findings in enzyme inhibition research.
The journal’s focus includes current developments in:
Enzymology;
Cell biology;
Chemical biology;
Microbiology;
Physiology;
Pharmacology leading to drug design;
Molecular recognition processes;
Distribution and metabolism of biologically active compounds.